For immediate release:

7/5/09
XL-6 enters Phase four testing. Six test markets announced for XL-6 Necro-mortosis inhibitor. All market sections are confidential at this point in time. Test period to continue under full assessment for up to six months.

3/10/09
XL-6 Necro-mortosis inhibitor stem cell research to continue.
Amcalon stocks gain 47%

3/9/09
US  has repealed outgoing administrations ban on stem-cell research.

9/9/08
Amcalon will be represented at the World Health Authority summit in Geneva on 10/12/08. A special XL-6 review board committee will be presented with the latest update on the inhibitor.

6/5/08
A second victim of contracted necro-mortosis has successfully recovered from early to mid stage necrotic contamination. Neus Vargas, a 67 year old woman was administered the XL-6 inhibitor along with a similar medical procedure used on Sile Koch in Germany's Hannover hospital last month.

Vargas is said to be showing promising signs of a complete recovery from her earlier necrotic state.

5/17/08
WHA approve financial XL-6 investment
Following the recent success on phase two testing in Hannover hospital, Germany. Amcalon is pleased to announce that the World Health Authority has agreed to a 15% cost leverage of all XL-6 mortosis inhibitor testing through phase two development.

5/10/08
Victim of undead attack administered XL-6 - in full recovery
A recent victim of a reanimate attack in Germany is continuing to make a full recovery following a procedure that included the administration of the XL-6 inhibitor.

The test drug was in a phase two preliminary 'standby' mode. It's usage, strictly coded and enforced, was used along with a  heating treatment designed to  maintain the  infected patients  core temperature.

The patient, Silke Koch, has since been released from hospital care and continues her recovery at an undisclosed location.

Read independent report:
http://www.zombieworldnews.com/archives/europe/hannover_victim_released.htm